ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1526

Development of Antinuclear Antibodies and Systemic Lupus Erythematosus in Patients on Tumor Necrosis Factor α Inhibitor Therapy

Chathura Wijewardena1, Paramarajan Pirinavan1, Sandy Nasr1 and Andras Perl2, 1SUNY Upstate Medical University, Syracuse, NY, 2State University of New York, Syracuse, NY

Meeting: ACR Convergence 2021

Keywords: Anti-TNF Drugs, Autoantibody(ies), Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 9, 2021

Title: Immunological Complications of Therapy Poster (1516–1529)

Session Type: Poster Session D

Session Time: 8:30AM-10:30AM

Background/Purpose: Tumor necrosis factor α (TNF-α) inhibitor therapy has been widely used worldwide as a potent immunosuppressant for a variety of rheumatological diseases. Induction of antinuclear antibodies (ANA) and systemic lupus erythematosus (SLE) in patients receiving anti-TNF-α therapy have been previously documented1. It is known that up to 15% of healthy individuals have a positive ANA test2. In this study we examined the frequency and safety outcomes of ANA and SLE induction following initiation of anti-TNF-α therapy.

Methods: Patients, age >18 years, from January 2012 – December 2020 who were newly prescribed the following TNF-α inhibitor were included in this study: golimumab, cetrolizumab, adalimumab, etanercept, infliximab and inflectra. They were categorized into two groups based on immune fluorescence ANA assay performed either before or after anti-TNF-α therapy was started. The ANA tested cohort was sub-categorized to ANA-positive and ANA-negative result. ANA positive patients were sub-categorized for ANA ‘positivity before’ or ‘positivity after’ TNF-α inhibitor start date. Fisher’s exact two tailed test and two tailed chi-square was calculated on the GraphPad Prism 9.0 statistical software; two-tailed p values < 0.05 were considered significant.

Results: 2803 patients met inclusion criteria. 1120 were and 1683 were not tested for ANA. Of 1120, 742 had a positive test and 378 had a negative test result. From 742, 508 and 234 had a positive ANA test before and after the initiation of a TNF-α inhibitor, respectively. Percentage developing a positive ANA test following anti-TNF-α was 20.8% (234/1120). 83 patients had SLE before and 32 developed clinician diagnosed SLE after TNF-α inhibitor. There was a statistically significant difference on the impact on ANA induction and development of SLE (Table 1).

32 patients met ACR or SLICC criteria for SLE (Table 2). Arthritis and synovitis had to be present before TNF-α inhibitor was started in these 32 patients. TNF-α was discontinued in 22 and continued in 10 (Table 3). No life-threatening SLE complications, hospitalizations, or death were noted in patients with TNF-α inhibitor-induced SLE.

Conclusion: The data from our cohort newly prescribed anti-TNF-α therapy demonstrate the autoimmunity which should be carefully monitored for adverse events attributable to the development of SLE. Timely discontinuation, less than a week from identification of TNF-α induced SLE, appears to have prevented serious SLE-related adverse events. Additionally, we show that compared to healthy persons that the prevalence of a positive ANA test is higher in TNF-α treated patients, 15% vs. 20.8%.

References:
1. Williams VL, Cohen PR. TNF alpha antagonist-induced lupus-like syndrome: report and review of the literature with implications for treatment with alternative TNF alpha antagonists. Int J Dermatol 2011; 50:619.

2. Bhana,S.(2019). Antinuclear Antibodies (ANA). ACR. Retrieved from https://www.rheumatology.org/I-Am-A/Patient-Caregiver/Diseases-Conditions/Antinuclear-Antibodies-ANA


Disclosures: C. Wijewardena, None; P. Pirinavan, None; S. Nasr, None; A. Perl, None.

To cite this abstract in AMA style:

Wijewardena C, Pirinavan P, Nasr S, Perl A. Development of Antinuclear Antibodies and Systemic Lupus Erythematosus in Patients on Tumor Necrosis Factor α Inhibitor Therapy [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/development-of-antinuclear-antibodies-and-systemic-lupus-erythematosus-in-patients-on-tumor-necrosis-factor-%ce%b1-inhibitor-therapy/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/development-of-antinuclear-antibodies-and-systemic-lupus-erythematosus-in-patients-on-tumor-necrosis-factor-%ce%b1-inhibitor-therapy/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology